BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210504
DTEND;VALUE=DATE:20210507
DTSTAMP:20260515T172515
CREATED:20210203T083221Z
LAST-MODIFIED:20210203T083221Z
UID:28753-1620086400-1620345599@www.pharmajournalist.com
SUMMARY:Multi-Functional Cell Therapies Summit
DESCRIPTION:Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies\, to Deliver Best-in-Class Products to Patients in Need\nCell therapies hold life-saving potential for patients\, and the race is on to develop best-in-class\, living\, ‘thinking’ drugs. Relapse rates and barriers to solid tumor efficacy mean the cell therapy industry must innovate\, now more than ever.  \nThe inaugural Multi-Functional Cell Therapies Summit gathers the avantgarde to discuss strategies to weaponize cell therapies with antigenic\, engineered and combination approaches to create sophisticated\, multi-functional systems. \nFor more details about the program\, speaker faculty or pricing and discounts\, download the brochure.
URL:https://www.pharmajournalist.com/event/multi-functional-cell-therapies-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210505
DTEND;VALUE=DATE:20210507
DTSTAMP:20260515T172515
CREATED:20210121T121615Z
LAST-MODIFIED:20210121T121835Z
UID:28605-1620172800-1620345599@www.pharmajournalist.com
SUMMARY:Chronic Hepatitis B Drug Development Summit
DESCRIPTION:The first ever meeting purpose-built for discussing the advancement of curative therapies for chronic HBV infection.  \nFeaturing an all-star speaker faculty from across industry\, NGOs and academia\, all dedicated to finding a curative therapy for Chronic HBV infection.  This is a unique opportunity to review the latest clinical investigations with novel and classic therapeutics including RNAi and immuno-therapies. \n \nHere is just a snapshot of some of the speakers who are joining us: \nYuchun Nie\, Senior scientist\, Aligos Therapeutics\nGaston Picchio\, Chief Development Officer\, Arbutus Biopharma\nWilliam Delaney\, Chief Scientific Officer\, Virology\, Assembly Biosciences (USA)\nStephane Daffis\, Scientist II\, Gilead Sciences\nPatricia Mendez\, Vice President – Clinical Development\, Immunocore Ltd\nAndrew Vaillant\, Chief Scientific Officer\, Replicor Inc.\nTom Evans\, Chief Scientific Officer\, Vaccitech\nDavid Anderson\, Chief Scientific Officer\, VBI Vaccines Inc. \nDon’t miss out on this opportunity to benchmark yourself against the competition\, get a comprehensive update on how the field stands and network with peers from across the field at the inaugural Chronic Hepatitis B Drug Development Summit.  Find out more >> https://ter.li/haruyt
URL:https://www.pharmajournalist.com/event/chronic-hepatitis-b-drug-development-summit/
LOCATION:Virtual Summit
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210510
DTEND;VALUE=DATE:20210512
DTSTAMP:20260515T172515
CREATED:20210205T092218Z
LAST-MODIFIED:20210205T092218Z
UID:28774-1620604800-1620777599@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual Highly Potent Active Pharmaceutical Ingredients Conference (HPAPi)
DESCRIPTION:Innovations in HPAPI Containment & Facility Design for Successful Manufacturing \nSponsored by: Catalent Pharma Solutions and FPS Food and Pharma Systems \nChaired by: Justin Mason-Home\, Director\, HPAPI Project Services Limited \nSMi is delighted to announce its 5th Annual Highly Potent Active Pharmaceutical Ingredients Virtual Conference on 10th and 11th May 2021. \n \nHighly Potent Active Pharmaceutical Ingredients (HPAPIs) play an increasing central role in the fight against many diseases. There is an increasing need to protect workers who handle HPAPIs along the life cycle of the drug product manufacturing\, from synthesis of the pharmaceutical active ingredient to distribution of the finished medicinal product. This year’s event will focus on 4 key themes: best practices for toxicological assessment\, innovations in containment and facility design\, advances in the use of robotics and automation in manufacturing processes\, and environmental considerations. Key case studies will be highlighted throughout these themes\, revealing the key challenges for current HPAPI manufacture\, and insights into the latest technological and regulatory advances in this increasingly potent environment. \nAttend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPi industry. \nKey Speakers for HPAPi include: \n\nEster Lovsin-Barle\, Head of Product Stewardship and Health\, Takeda\nRichard Denk\, Senior Consultant Aseptic Processing & Containment\, SKAN AG\nRaphael Nudelman\, Director of Chemical & Computational Toxicology\, Teva Pharmaceutical\nOlindo Lazzaro\, Director Global EHS\, AbbVie\nFred Ohsiek\, Senior Specialist\, Cleaning Validation\, Novo Nordisk\nFlorian Grundmann\, MSAT Team Lead\, Cleaning Validation\, Roche\nIldiko Ziegler\, QA Manager\, Vanessa Research\nJack Brown\, Senior Research Fellow\, formerly Boehringer Ingelheim\nReinhold Maeck\, Head of Corp EHS Regulatory Intelligence\, Boehringer Ingelheim\n\nDoreen Parrish\, Head of Corporate Audit\, Global EHS\, Takeda \nKey Reasons to Attend HPAPi: \n\nExplore best practices in hazard assessment and occupational toxicology\nunderstand strategic considerations for planning pilot plants and scaling up manufacturing capabilities for high potency compounds\ndiscover potential for automation and robotics in pharmaceutical manufacturing and technologies for protecting operators from hazardous substances\ndiscuss the opportunities for effective CDMO relationships and explore methods for strengthening those partnerships\nDelve into the expanding ADC market within and beyond oncology\nVirtual conference benefits include virtual exhibition booths packed with information\, networking features to chat and share contact details with attendees\n\nView the full agenda: www.highlypotentapi.com/PJwl
URL:https://www.pharmajournalist.com/event/smis-5th-annual-highly-potent-active-pharmaceutical-ingredients-conference-hpapi/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210510
DTEND;VALUE=DATE:20210512
DTSTAMP:20260515T172515
CREATED:20210305T123955Z
LAST-MODIFIED:20210308T094548Z
UID:29277-1620604800-1620777599@www.pharmajournalist.com
SUMMARY:SMi’s 21st Annual Pain Therapeutics Conference
DESCRIPTION:Sponsored by: MD Biosciences and Transpharmation \nChaired by Michael Scherz\, Founder & CEO\, Metys Pharma and Naheed Mirza\, Early Development Pain & CNS Specialist \nExplore Cutting Edge Drug Discovery Science and Key Clinical-Stage Pain Therapies in the Pipeline \nSMi’s 21st Pain Therapeutics Conference will focus on looking into research within pain therapeutics. In particular\, the long-term (HEAL) initiative will be discussed and its role in advancing research to reduce the risks of opioid use and misuse and improve pain management\, thereby reducing reliance on opioids and the national opioid public health crisis.  Talks will also address the importance of sex\, gender and race in pain research\, including biomarkers\, molecular targets\, clinical and experimental models of pain. \n \nThe conference also address cutting edge drug discovery science\, preclinical development trends\, analysis of key clinical-stage pain therapies\, with a focus on highlighting the importance of biomarker discovery and its contribution to early stage studies on pain. This will be topped off with a panel debate on rethinking pain clinical trials during the COVID-19 pandemic. And further look into treating painful osteoarthritis of the knee with a novel anti NGF\, anti-TNFα bispecific fusion protein as well as therapeutic novelties signifying a paradigm shift in migraine prevention. Additionally\, the conference will explore Botulinum neurotoxin\, Sigma 1 proteins and AP-325 as novel treatment for neuropathic pain as well as the high unmet medical need to develop a novel non-drowsy skeletal muscle relaxant and explore pain genetics in rare diseases as well as the Opioid Crisis and the future of addiction and Pain Therapeutics. \nJoin Europe’s leading Pain Therapeutics Virtual Conference in May 2021 to explore cutting edge drug discovery science and key clinical-stage pain therapies in the pipeline\, bringing together leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.\n#SMiPain \nKey Reasons to Attend the Conference: \n\nDiscover which innovative new therapies are driving clinical development including case studies from Novaramed and Vapogenix\nExamine the best strategies to generate more funding in pain research clinical trials to eliminate the issue of underfunding\nExplore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification\, data analysis and data collection\nUnderstand the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy\nVirtual Conference Benefits include virtual exhibition booths packed with information\, networking features to chat and share contact details with other attendees\, and virtual meetings and networking socials.\n\nWHO SHOULD ATTEND \nChief Executive Officer\, Chief Scientific Officers\, Chief Medical Officers\, Managing Directors\, CEO\, Head of Department\, Principal Research Scientists\, Clinical lead\, Clinical Operations in the following fields: \n\nPain and Migraine\nInflammation\nChronic Pain\nNeuropathic Pain\nAnalgesic pre-clinical development\nAnaesthesia and Pain Management\nCNS clinical trials\nIon Channel Pharmacology\nPharmacology Intelligence\nTranslational science\nDrug development\nExploratory development\n\nView the full agenda: http://www.pain-therapeutics.co.uk/PJwl
URL:https://www.pharmajournalist.com/event/smis-21st-annual-pain-therapeutics-conference/
LOCATION:Virtual Conference – Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:EVENTS@SMI-ONLINE.CO.UK
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210511
DTEND;VALUE=DATE:20210514
DTSTAMP:20260515T172515
CREATED:20210208T104245Z
LAST-MODIFIED:20210208T104245Z
UID:28869-1620691200-1620950399@www.pharmajournalist.com
SUMMARY:Manufacturing Assets and Facility Management in Pharma Summit 2021
DESCRIPTION:Manufacturing Assets and Facility Management in Pharma Summit returns in 2021. Taking place virtually this May 11-13\, a must attend event to help modernize your facility and revitalize your asset management strategies. Join this cutting-edge discussion and network with engineering\, maintenance and manufacturing facilities leaders. \nTo know more about Manufacturing Assets and Facility Management in Pharma Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/manufacturing-assets-and-facility-management-in-pharma-summit-2021/
LOCATION:Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210512
DTEND;VALUE=DATE:20210514
DTSTAMP:20260515T172515
CREATED:20200108T084240Z
LAST-MODIFIED:20200604T152104Z
UID:23563-1620777600-1620950399@www.pharmajournalist.com
SUMMARY:Injectable Drug Delivery 2021
DESCRIPTION:Assessing the innovations in formulations and devices for enhanced injectable delivery  \nSMi Group is pleased to announce the third annual Injectable Drug Delivery conference\, which will be held in London on the 12th and 13th May 2021. \nPart of Europe’s leading Injectable conference series\, Injectable Drug Delivery will assess innovations in drug product formulation and biologics\, innovations in device design\, quality management and connectivity for enhanced subcutaneous delivery. \n \nWith rapid developments in the parenteral space\, the injectable drug delivery market is set to reach USD 902.3 billion by 2027\, with an increased focus on patient centricity during DDC development and innovations in device development\, including new therapeutic applications such as the delivery of siRNA. This year’s event will focus on advances in drug product formulation and innovations of device design and development to aid delivery. \nFurthermore\, the conference will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines. \nThe two-day agenda also offers peer-to-peer networking with Global Product Managers\, Device Testing Managers\, Senior Device Engineers\, Heads of Device Development\, Heads of Formulation and Drug Process Development\, and many more. \nThe benefits of attending: \nThis conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following: \n\nDELVE into the latest work in complex formulation for subcutaneous delivery\nBENCHMARK against leading pharma companies working to enhance device design and development\nUNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors\nENGAGE in industry case studies on design controls\, human factors and parenteral formulation\nEXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers\, Scientists\, Researchers of: \n\nAutoinjectors\nWearables\nDevice Engineering\nHuman Factors\nCMC\nInjectables\nSterile Manufacturing\nPackaging\nRegulatory Affairs\n\nFeatured Speakers: \n\nAlexander Zuern\, Device testing manager\, Novartis International AG\nAndrew Warrington\, Project Leader & Patient Advocate\, Novartis\nBenjamin Werner\, Scientist\, Boehringer Ingelheim Pharma GmbH & Co. KG\nBjorg K Hunter\, Regulatory Manager\, Devices\, GSK\nBlake Green\, Senior Manager Regulatory Affairs\, Amgen\nCamille Dagallier\, Formulation and Drug Process Development Senior Scientist\, Sanofi\nChristopher Muenzer\, Senior Device Technology Manager\, Novartis\nJoel Richard\, Head of Technical & Pharmaceutical Operations\, MedinCell\nMark Palmer\, Scientific Leader\, Biopharm Device Engineering\, GSK\nRebecca Moses\, Director\, Core Human Factors Inc.\nRupal Nguyen\, Principal Engineer\, Allergan\nStefania Ragone\, Pharmaceutical Assessor\, Medicines & Healthcare Products Regulatory Agency (MHRA)\nTina Arien\, Principal Scientist\, Janssen Pharmaceutica\nVikas Jaitely\, Director\, Global Regulatory Affairs Transitional Medicine and Devices\, Merck\n\nLinkedIn: @SMi Pharma\nTwitter: @SMiPharm #SMiInjectables
URL:https://www.pharmajournalist.com/event/injectable-drug-delivery-2021/
LOCATION:St. James’ Court\, 54 Buckingham Gate\, Westminster\, London\, SW1E 6AF\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210518
DTEND;VALUE=DATE:20210521
DTSTAMP:20260515T172515
CREATED:20210211T103519Z
LAST-MODIFIED:20210211T103816Z
UID:28913-1621296000-1621555199@www.pharmajournalist.com
SUMMARY:Genetic Vaccine Development for Infectious Diseases Summit
DESCRIPTION:The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need\, unprecedented investments\, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality\, but our future. \n \nWith pandemic vaccines now launching at record speeds\, the first Genetic Vaccine Development for Infectious Diseases Summit will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases\, including Influenza\, Lassa fever\, Ebola\, MERS\, HIV\, Zika\, and COVID-19. \nWith a focus on mRNA\, DNA\, and engineered viral vector-based vaccines\, this niche 3-day agenda has been specifically designed to help industry experts to discuss new genetic-based vaccine platforms\, preclinical and clinical case studies\, optimized delivery methods\, and the future of vaccine R&D to usher in a new era of vaccinology\, with experts from BioNTech\, Pfizer\, Moderna\, AstraZeneca and CureVac. \nTo know more about Genetic Vaccine Development for Infectious Diseases Summit please\nclick here.
URL:https://www.pharmajournalist.com/event/genetic-vaccine-development-for-infectious-diseases-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210520
DTEND;VALUE=DATE:20210522
DTSTAMP:20260515T172515
CREATED:20210226T102847Z
LAST-MODIFIED:20210226T102847Z
UID:29162-1621468800-1621641599@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets Bioprocessing of Biotherapeutics-UK\,EU & APAC-Virtual
DESCRIPTION:After the successful four editions of Bioprocessing of Cell therapies\, coming up with 5th Annual of Bioprocessing of Biotherapeutics brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development\, manufacture and quality of protein expressions\, cell\, and gene therapies. \nThe virtual event will present detailed case studies and interactive discussions in cell culture\, scale-up\, continuous processing\, recovery\, purification\, process and product characterization\, and formulation. \nEvent Website: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-bioprocessing-of-biotherapeutics-uk-eu-apac-virtual/ \nRegistration link:  https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-bioprocessing-of-biotherapeutics-uk-eu-apac-virtual/register 
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-bioprocessing-of-biotherapeutics-ukeu-apac-virtual/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T172515
CREATED:20201210T121300Z
LAST-MODIFIED:20201210T121300Z
UID:28242-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Ligase Targeting Drug Development – Digital Summit
DESCRIPTION:As the therapeutic value of manipulating previously hard-to-drug ubiquitin ligases becomes more and more evident in addressing numerous diseases with unmet clinical needs\, the inaugural Ligase Targeting Drug Development Summit arrives as the dedicated scientific and networking forum for large pharma\, innovative biotech and research institutes to seize the day. \n \nBuilt with large pharma and biotech insight\, the Ligase Targeting Drug Development Summit is fully dedicated to enabling novel ligase discovery and characterization\, achieving cell and tissue specificity and expanding chemical biology tools to therapeutically leverage ubiquitin ligases for effective protein modulation or degradation strategies. \nAs leading pharma companies join forces to bridge the gap between the functional knowledge and true translational value of ubiquitin ligases and their associated ligands\, join us to advance your understanding\, differentiate your pipelines and tap into the uncapped therapeutic potentials of this emerging field. \nTo know more about Ligase Targeting Drug Development – Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/ligase-targeting-drug-development-digital-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T172515
CREATED:20210118T161111Z
LAST-MODIFIED:20210118T161111Z
UID:28556-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Gene Therapy for Muscular Disorders
DESCRIPTION:With clinical holds lifting there has been more investment and clinical progress in the gene therapy for muscular disorders space than ever before\, yet the consequences of toxicity are not a distant memory. Despite the successes\, there are still withstanding challenges for gene therapy developers targeting the muscle when it comes to optimizing delivery and navigating toxicity to develop truly safe and transformative therapeutics for muscular disorders patients. \n \nThe first industry-dedicated Gene Therapy for Muscular Disorders Summit will focus on overcoming the translational and clinical challenges of developing genetic therapies targeting muscular disorders\, including Duchenne Muscular Dystrophy (DMD)\, Limb-Girdle Muscular Dystrophy (LGMD)\, Pompe Disease and X-Linked Myotubular Myopathy. \nWith a focus on AAV and gene editing technologies and insights from Pfizer\, Solid Biosciences\, Audentes and Vertex\, this niche 3-day agenda has been specifically designed to help industry experts to: \n\nOptimize your promoter choice and navigate IP challenges for more efficient delivery to muscular targets\nDiscover the next generation capsids being developed for improved muscle selectivity and reduced immunogenic responses\nUnderstand the biology of different immunogenic responses and hear feedback from trialled strategies to ensure optimal patient safety\nHear the latest research in muscular disorder biomarkers\nDefine clinically meaningful muscular endpoints to successfully and objectively measure muscular disease improvement\nTackle regulatory challenges to demonstrate gene therapy durability\nOvercome clinical challenges to manage patient heterogeneity for patient centric and meaningful trials\n\nJoin your peers to share\, learn and discuss at the first industry-focused Gene Therapy for Muscular Disorders. Overcome your immunogenicity challenges and mitigate toxicity with high doses targeting the muscle to successfully demonstrate durability with your gene therapy product. \nTo know more about Gene Therapy for Muscular Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-muscular-disorders/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T172515
CREATED:20210208T082747Z
LAST-MODIFIED:20210208T090154Z
UID:28850-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Maternal & Infant Health Summit 2021
DESCRIPTION:Harness the Maternal-Infant Microbiome\, Establish New Mechanisms of Action\, and Develop Breakthrough Health Products that Proactively Prevent Disease Risk  \nReturning for another year\, this platform will unite industry and academics in the exploration of preventative and therapeutic treatment of the microbiome during pregnancy and early life. The discussion during this 3-day conference will cover key periods of pregnancy\, birth and infant development to encompass a range of areas where therapeutic\, nutritional targeting and research can be undertaken. \nTake this opportunity to join the event and you can:   \n\nGain a complete understanding of the current research and therapeutic opportunities as we walk through the infant journey from in utero development through to the first 1000 days\nUnderstand the value of the mother’s experience and health for foetal development with talks from Siobhain O’Mahony and Mary Claire Kimmel\nDiscover new therapeutic research into the vaginal microbiome\, such as PhagoMed and Columbia University \nBuild a broader understanding of the benefits of prevention with Evolve Biosystems highlighting cost-saving from early life treatments and the NIH’s push to advance this area of science\nHear from Siolta Therapeutics and ParetoBio in developing therapeutic treatments for allergies\n\nJoin us to further your understanding of how cutting-edge science is helping establish a causal relationship between the maternal-infant microbiome and long-term health effects\, and how this can be translated to demonstrate clinically validated solutions. \nTo know more about 3rd Microbiome Movement – Maternal & Infant Health Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-maternal-infant-health-summit-2021/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T172515
CREATED:20210215T090719Z
LAST-MODIFIED:20210215T090719Z
UID:29000-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:STING & TLR-Targeting Therapies Summit
DESCRIPTION:This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches. \nThis meeting comes at a critical point for the cancer immunotherapy field\, as researchers look to increase patient response rates and the efficacy on checkpoint inhibitors in several solid tumor indications. Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising. \n \nUse this key forum to hone your innate immune activation strategies and deliver safe and effective treatments through systematic and intra-tumoral administration which can stimulate the adaptive immune arm\, counteract solid tumor-induced immunosuppression and increase response to checkpoint inhibitors. \nView the event guide for the full agenda! \nInnate Immune Checkpoints & Activation Pre-Focus Day \nIn addition to two full conference days to STING/TLR-targeting\, there will be a pre-focus day specifically on innate immune checkpoints and the activation of specific cell types including natural killer cells\, macrophages and myeloid-derived suppressor cells. \nAn executive speaker faculty will take you through the leading drug candidates aimed at inhibitory and activation receptors on key cellular component of the innate immune system. \nView the full event guide for more information.
URL:https://www.pharmajournalist.com/event/sting-tlr-targeting-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T172515
CREATED:20210312T064902Z
LAST-MODIFIED:20210312T065621Z
UID:29303-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Gene Therapy Analytical Development Europe
DESCRIPTION:In the context of unprecedented gene therapy investment and clinical progress\, with mounting regulatory scrutiny\, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency\, quality\, and safety of gene therapy products. \n \nWhether you’re looking for specific characterisation\, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past\, this focused\, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors\, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. \nJoin 150+ analytical pioneers to discover the realities of working with tools like dPCR\, AUC and HPLC\, as well as how and where these tools can be most effective in process development\, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \n To know more about Gene Therapy Analytical Development Europe please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-analytical-development-europe/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:https://ter.li/8f5rxa
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T172515
CREATED:20210318T083358Z
LAST-MODIFIED:20210318T120953Z
UID:29402-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Inner Ear Disorders Therapeutics Summit – Digital Event
DESCRIPTION:Hearing loss has a huge impact on the quality of life for millions of people\, and as the average age of the population increases\, the need for curative life-changing therapies targeting hearing loss and inner ear disorders has never been more important. \n \nThe Inner Ear Disorders Therapeutics Summit is gathering the world’s leading biopharmaceutical companies and KOLs at the only industry-focused summit dedicated to the translation and clinical development of novel gene therapy\, cell therapy and small molecule-based approaches to treat inner ear disorders\, with the aim to progress the industry towards the first clinically approved therapy. \nJoin industry and academic experts to discuss the best preclinical modelling approaches for translative proof of concept data\, identify the most appropriate biological endpoints and overcome the major challenges to develop safe\, effective\, and clinically viable inner ear disorder therapies to address the unmet medical need. \nTo know more about Inner Ear Disorders Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/inner-ear-disorders-therapeutics-summit-digital-event/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR